Sort   by:  
 Page size 
UnknownTumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Not available
S-EPMC6608613 | biostudies-literature
UnknownA phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Not available
S-EPMC11164811 | biostudies-literature
UnknownPralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
Not available
S-EPMC3083873 | biostudies-literature
UnknownIDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Not available
S-EPMC3293643 | biostudies-literature
UnknownPredicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
Not available
S-EPMC8627688 | biostudies-literature
UnknownRandomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Not available
S-EPMC4148765 | biostudies-literature
UnknownInternational Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Not available
S-EPMC5834038 | biostudies-literature
UnknownAdjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Not available
S-EPMC5840256 | biostudies-literature
UnknownFLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.
Not available
S-EPMC12674000 | biostudies-literature
UnknownAdjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Not available
S-EPMC6722042 | biostudies-literature
Sort   by:  
 Page size